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Abstract
Background: Recent meta-analyses suggested that screening program for abdominal aortic aneurysms (AAA) in
65-year old males is cost-effective at prevalence of about 1%. Since some events occur also in females and among
the youngers, screening could be feasible among those at higher risk, such as smokers or individuals with a family
history of AAA. The RoCAV (Risk of Cardiovascular diseases and abdominal aortic Aneurysms in Varese) Project is a
population-based study aimed to evaluate AAA prevalence in Northern Italy in males over-65 years as well as
among females and younger males, and to identify new markers for risk stratification by collecting a large set of
CVD risk factors. The aims of the project are: (i) cross-sectional evaluation of AAA prevalence (ii); evaluation of
standard CVD risk score as criteria for selecting subgroup at higher risk to be included in a screening program; (iii)
identification of new risk markers and risk score algorithm for AAA and CVD risk stratification; (iv)
cost-effective evaluation during the follow-up.
Methods: Males aged 50–75 years and females aged 60–75 years, resident in the city of Varese (Lombardy Region),
were randomly selected from the civil registry. Among 5198 successfully invited, 3777 subjects accepted to
participate and were finally recruited (participation rate 63.8%) from June 2013 to May 2016. Trained operators
administered a computerized anamnestic questionnaire, measured anthropometric parameters (BMI, body
circumferences, skinfolds), blood pressure, ankle-brachial index, pulse wave velocity and performed abdominal
aortic ultrasound scan, ECG and spirometry. All methods were internationally validated. A blood sample was
collected and stored in biobank. A follow-up will be carried out through linkage with electronic records.
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Discussion: Participation rate and data quality assessment were as expected and will reasonably allow to reach the
project aims. The expected impact in public health of the RoCAV project will be the potential implementation of a AAA
screening program to the whole region as well as the formulation of new criteria for risk assessment of AAA and CVD.
Keywords: Abdominal aortic aneurysm, Cardiovascular risk, Vascular diseases, Population based study, Screening, ABI,
PWV, Electrocardiography, Spirometry, Diet
Background
Abdominal aortic aneurysm (AAA) is a very common dis-
ease in Western Countries, mainly among males older
than 65-years (prevalence of 4–7%), although the preva-
lence is decreasing in the last years [1, 2]. Large AAA are
at increasing risk for rupture, with high mortality (ap-
proximately 80% fatal), therefore AAA must be early iden-
tified, followed-up and then treated with elective repair.
AAA is a disease well-suited to screening according to
the WHO criteria [3]. Recent meta-analyses suggested
that screening programs for abdominal aortic aneurysm
in 65-year old males reduce all cause and AAA-specific
mortality and are cost-effective where disease prevalence
is 1% or higher. Recent screenings showed a prevalence
of 1.1–1.7% in 65-years old individuals. However data
from the general population are available only for North-
ern Europe, UK and Australia [4–11]. Furthermore,
some events occur also in females and in youngers than
65 years. Country-specific data showed that in these sub-
groups the AAA prevalence is low and then there is no
consensus on the cost-effectiveness of a screening pro-
gram. However it could be suggested in smokers or in
presence of a family history [12, 13]. Future studies are
needed to identify other risk factors and test their utility
as risk stratification markers, to improve feasibility of
screening programs as well as to target subgroups at
higher risk with primary prevention interventions.
AAA is the result of a loss of elastic lamina and
smooth muscle cells, which could be due to inflamma-
tory agents and matrix metalloproteases [14]. The main
risk factors found associated with AAA are age, sex,
smoking, hypertension and family history of AAA, as
well as previous cardiovascular diseases (CVD) [15, 16].
For this reason, the use of standard CVD risk score as
well as the presence of a previous CVD could be useful
to select subgroups at higher risk to screen for AAA.
However, part of the phenotypic variability in the popu-
lation remains unexplained, probably due to other risk
factors or to interactions with the genetic and epigenetic
background [17, 18]. Population based studies with the
availability of biobank samples could be useful to enlarge
the focus on further biomarkers. An AAA risk score
algorithm could be evaluated as a criteria to select sub-
groups of patients at higher risk to be included in a
screening program.
Few data are available for Southern European popula-
tions, both for prevalence and risk factors, and actually
there are no national screening programs. The RoCAV
(Risk of Cardiovascular diseases and abdominal aortic An-
eurysms in Varese) Project is a population-based cohort
study, aimed to evaluate AAA prevalence in Northern
Italy even among females and males youngers than 65,
and to identify new markers for risk stratification. Further-
more, a huge number of risk factors and diseases was col-
lected, mainly for cardiovascular area, which allow to
verify the potential of CVD risk score algorithm [19–21]
in AAA risk assessment, as well as to identify new risk
markers for a broad spectrum of cardiovascular diseases.
Some studies on screening programs of cardiovascular
diseases suggested their potential implementation in
healthcare settings, although effectiveness has yet to be
improved [22]. In fact, conditions at higher cardiovascular
risk such as hypertension, hyperglycemia, dyslipidemia,
atrial fibrillation are often identified late. The specific aims
of the project are: (i) cross-sectional evaluation of AAA
prevalence in males starting from 50 years old (50–75
years) and in older females (60–75 years) (ii); potential
utility of standard CVD risk score to select subgroups at
higher risk to be included in a screening program; (iii)
identification of new risk markers and algorithms for
AAA and CVD disease risk stratification; (iv) cost-
effective evaluation during the follow-up.
Methods
Epidemiological design and study population
The RoCAV study is a population-based cohort study.
Participants were citizens of Varese (79,793 inhabitants
in Lombardy Region, Northern Italy), the main city in a
district area of 1 million inhabitants. The civil registry
was obtained and 6400 subjects were randomly selected
among 50–75 years old males and 60–75 years females,
at 30 June 2013, through randomization stratified for sex
and 5-years classes (800 subjects for each class) using R
software. No exclusion criteria was used. The study was
approved by the Varese Hospital Ethical Committee.
Recruitment
The recruitment of participants started in June 2013 and
end in May 2016. An invitation was sent to the partici-
pant address by regular mail. The letter included the
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consent form and the related project information for a
preliminary view, along with a suggested date for the
examination in our hospital department and a phone
number to be contacted for confirmation. An overnight
fasting was required. Non-responders were newly con-
tacted by a second letter and then by phone, whenever a
phone number was available. The address list was up-
dated periodically to reach citizens who have changed
address within the city. In case of refusal, the reported
reason was recorded, along with previous diagnosis of
AAA. No exclusion criteria were used. A letter was sent
to all the GPs of the surrounding area to make them
conscious of the possibility for recruitment for their
patients and to ask their collaboration in improving the
patient participation to the project.
Among 6167 subjects invited, 249 did not received the
letter (changed address, death during recruitment).
Among the residual 5918 invited, 3777 subjects were fi-
nally recruited (65.5 ± 6.7 years; participation rate 63.8%;
details for sex and age classes are shown in Table 1). Men
showed higher participation rate than women (65.3% vs
61.3%), mainly among the elderly. A total of 692 individ-
uals declared their refusal to participate by phone, mainly
due to lack of interest (44.8%; Table 2). Among them, nine
(1.3%) subjects declared to have already a known AAA.
Differences in demographic characteristics between re-
sponders and non-responders are shown in Table 3. Men
(59.6% among non-responders vs 63.7% among recruited;
p = 0.002) and married individuals (67.8% vs 78.2%; p <
0.0001) were more willing to participate.
Data collection
In our hospital departments, a trained operator pre-
sented the project and asked to sign the informed con-
sents (study participation and blood sample storage for
future analyses). Then a team of trained operators took
blood pressure measurements and collected a blood
sample, followed by collection of anamnestic, clinical
and instrumental data. The methods adhered to the
standardized procedures and quality standards of the
European Health Examination Survey (EHES) [23], the
WHO Multinational MONItoring of trends and deter-
minants in CArdiovascular disease (MONICA) Project
[24] and the European Prospective Investigation into
Cancer and Nutrition (EPIC) study [25]. All procedures
were standardized during training sessions.
A barcode was assigned to the participants to reduce
error rate in matching with own electronic folder. A
software managed the data collection procedures, as well
as recruitment, booking and blood sample storage. Test
results were sent to participants and their GPs. Follow-
up will start soon using electronic medical records.
Anamnestic questionnaires
Standardized, computerized anamnestic questionnaires
were administered to the participants, regarding: socio-
economic status, lifestyles (smoking, physical activity)
and occupational, family (AAA, cardiovascular diseases
and cancer in first degree relatives), clinical and pharma-
cological history. A detailed questionnaire on diet habits
was also used (EPIC questionnaire [25]), which includes
graphic representations of food types and sizes to facili-
tate the participant choices. This latter questionnaire
was self-administered, with aid from operators to deal
with difficulties whenever needed.
Anthropometric measurements
Body weight and height were measured on a standard
beam balance scale with an attached ruler, in subjects
wearing only light indoor clothing (no shoes). Body mass
Table 1 Participation rates for the overall sample and stratified for sex and age classes
Males Females Total
Participants (N) Invited (N)b Rate (%) Participants (N) Invited (N)b Rate (%) Rate (%)
50-54a 295 503 58.6 - - - 58.6
55–59 490 752 65.2 - - - 65.2
60–64 465 698 66.6 315 503 62.6 65.0
65–69 525 777 67.6 479 747 64.1 65.9
≥70a 629 950 66.2 579 988 58.6 62.3
All 2404 3680 65.3 1373 2238 61.3 63.8
aInvitation letters were sent during all the recruitment time, this caused a shift towards older classes
bSubjects who did not receive the letter (changed address, death during recruitment; n = 249) were excluded
Table 2 Reasons given for refusing to participate (N = 692)
Reasons N %
Not interested in the study 310 44.8
Already under follow-up for a disease 192 27.7
Bedridden or in a retirement home 84 12.1
Recently dead 76 11.0
Recently moved out of the city 21 3.0
Not interested due to previous AAA diagnosis 9 1.3
Total 692 100.0
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index (BMI) was calculated as weight(kg)/(height(m)2.
Waist and hip circumferences were measured according
to the National Institutes of Health, Heart, Lung, and
Blood Guidelines [26]. Mid-upper arm muscle circum-
ference was also measured. A panel of skinfolds was
collected (biceps, triceps, subscapular, suprailiac, mid-
axillary, chest, abdomen and thigh) using a professional
caliper (GIMA Spa, Gessate, Italy), with precision
0.2 mm and range 0–40 mm.
Blood pressure and heart rate
Trained medical doctors took blood pressure according
to standardized protocol [23, 27]. Measurements were
made in a quiet room with comfortable temperature
with the participants sitting down for at least 5 min.
Blood pressure was measured using a standard sphyg-
momanometer, with larger cuff where arm circumfer-
ence was >34.0 cm. The peak inflation level was firstly
determined and then the first measurements started 30s
later. Blood Pressure was then measured three times on
the dominant arm waiting 1 min between measure-
ments, deflating the cuff at a rate of 2 mmHg per sec-
ond. The radial pulse was palpated and the pulse rate
was counted for 60 s, between the first and the second
blood pressure measurements.
Abdominal aortic imaging
A trained vascular surgeon performed an abdominal aor-
tic ultrasound scan. The sonographers obtained the aor-
tic images using the leading edge-to-leading edge
method [28]. Anterior-posterior and transverse diame-
ters were measured using a Esaote scanner with a Con-
vex 3,5 MHz transducer (Esaote, Genoa, Italy), at the
following sites: the proximal aorta just below the super-
ior mesenteric artery, the juxtarenal tract at level of
renal arteries, the proximal infrarenal aorta 2 cm below
the renal arteries, the distal infrarenal aorta 1 cm above
the bifurcation, and the point of maximal infrarenal aor-
tic diameter if different than the standard site measure-
ments. A 5-s video of the abdominal tract was also
registered. Files were stored and a vascular imaging
physician checked all images of ≥25 mm diameters plus
a 5% random sample. At the end of the recruitment
period, hospitalization and death records were searched
for the recruited subjects, along with prevalence and in-
cidence data for the overall city population from which
the sample was selected.
Ankle-brachial index (ABI) and pulse wave velocity (PWV)
Following the ultrasound scan, participants were tested
for ABI and PWV after 5 min rest in supine position. An
automated oscillometric measurement BOSO-ABI Sys-
tem (Bosch Sohn GmbH U. Co. KG, Jungingen,
Germany) was used, that allows simultaneous arm-leg
blood pressure measurements at the 4 limbs (twice, con-
sequent) and then the calculation of ABI and PWV [29].
Computerized ECG
Trained physicians performed electrocardiograms follow-
ing standard procedures [30]. Standard 12-lead resting
ECG was measured using a Cardioline electrocardiograph,
which acquires synchronized 10-s 12-lead ECG and trans-
mit the waveform data to a workstation in real time with a
bluetooth USB connection. Disposable electrodes were
used. Digital ECGs were stored in standard communica-
tion protocol-ECG format. Electrocardiographs were then
evaluated by a cardiologist.
Spirometry (peak expiratory flow)
Spirometry was performed by a trained physician using
the microQuark USB pc-based spirometer (COSMED,
Albano Laziale, Italy), while the patient was upright sit-
ting down. Three tests were obtained and the best result
was recorded. Forced vital capacity (FVC), forced expira-
tory volume in 1 s (FEV1), FEV1/FVC ratio, peak expira-
tory flow (PEF) and forced expiratory flow at 25, 50%
and 75% of FVC (FEF%) were collected.
Blood sample, laboratory analyses
A blood sample was collected from antecubital vein between
the hours of 8.00 and 9.30 a.m. from participants who had
fasted overnight. Fresh samples were split and sent to two
laboratories, for laboratory analysis and for storage in the
biobank. Blood cell count, serum lipids, blood glucose, cre-
atinine, γGT and transaminases levels were analyzed in the
centralized Hospital Laboratory on fresh samples, using
commercial reagents and automatic analyzers. LDL-
cholesterol was calculated using the Friedewald formula.
Biobanking
Blood samples in EDTA tubes (6 ml) and in serum-
separating tubes (3.5 ml) were marked with barcodes
and transferred to the lab within 1 h and 30 min, under
chain-of-custody and then processed within two hours.
All tubes were centrifuged 3200 rpm for 10 min, to sep-
arate the whole blood in serum (3 ml), plasma (3 ml),
buffy coat (1 ml) and red blood cells (2 ml), then col-
lected in 18 cryovials and stored in two refrigerators
Table 3 Differences between participants and non-responders
Participants Non-responders p-value§
N 3777 2141 -
Age Mean (SD) 65.5 (6.7) 65.5 (7.0) 0.95
Men n (%) 2404 (63.7) 1276 (59.6) 0.002
Marrieda n (%) 2900 (78.2) 1331 (67.8) <0.0001
§t-test (age) and chi-square (sex and civil status) were used
aMissing for 248 subjects (4.2%)
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(−80 °C). A specific software was developed to control
the entire procedure from assignment of barcodes to al-
location of cryovials, to improve and monitor the
process quality and comply with requirements for
preserving subject privacy. The RoCAV Biobank was ap-
proved by the local Ethical Committee. The procedures
met the national and regional guidelines, as well as the
international standards [31]. All participants enrolled
provided a specific written informed consent to giving
blood samples for genetic analysis and further biochem-
ical measurements. Considering refusal to biobank con-
sent and difficulty during blood sample and processing,
at the end of recruitment 67,102 cryovials for 3,731 pa-
tients were available in the biobank.
Follow-up
A follow-up will be carried out through record linkage
with electronic records during at least the next 10 years.
Total and cause-specific mortality, as well as major
CVD, thrombotic events and cancer will be searched
using the related ICD-10 codes.
Outcomes definitions
AAA was defined by a diameter of 30 mm or over in
juxtrenal, infrarenal or carrefour site. Further definitions
including different diameter thresholds and morphology,
specific for sex [32] or standardization using other vari-
ables such as anthropometric measures [33] will be con-
sidered, evaluating their reliability (AAA progression)
using follow-up data. The absence of exclusion criteria
allows to include previously known AAA cases in the
analyses, as well as to report the estimated total preva-
lence of the disease in the population along with the
screen-detected AAA prevalence.
Statistical analysis
The sample size calculation was drawn on previous litera-
ture in population based studies. Estimated prevalence of
AAA was 2–7% among males and 1% among females
older than 65-years, with decreasing values for youngers
(about 1% for male 50–65 years), therefore we expected to
recruit 4000 subjects and to find 100 cases of AAA at the
end of the recruitment, which allow to report powerful
sex-specific 5-year class prevalence. This sample size is in-
stead more powerful for the association analyses of AAA
diameters (continuous data) as well as of all other CVD
conditions at higher prevalence than AAA.
Data quality assessment according to MONICA proce-
dures [34] is on-going, details available at the Project
website [35].
According to the declared aims data analysis plan will
be: (i) cross-sectional evaluation of AAA prevalence in
the whole sample and in subgroups at high risk (ii);
CVD risk score analysis to stratify the sample in subjects
at different CVD risk classes to verify the AAA preva-
lence, using standard risk score for Italian population
(10-year risk score CUORE and SCORE, 20-year risk
score CAMUNI-MATISS [19–21]) or other risk score al-
gorithms recalibrated; (iii) analysis of the associations
between plausibly related risk factors and AAA as well
as CVD, in cross-sectional and longitudinal data using
multiple regression models, along with the analysis of
discrimination, number needed to screen to prevent a
rupture event and net benefit in risk stratification; (iv)
cost-effective analysis taking into account follow-up
data. All analyses will be carried out using the SAS stat-
istical package (version 9.4 for Windows. SAS Institute
Inc. Cary, N.C).
Discussion
Although screening program for AAA in 65-year old
males is reported to be cost-effective in Western
Countries [1], only few countries initiated such preventive
intervention, such as UK [36], Sweden [37] and US [38].
The main reason of the underuse of AAA screening pro-
gram is the lack of data for cost-effectiveness estimation.
One of the main determinants of screening cost-
effectiveness, along with country-specific healthcare set-
tings, is the disease prevalence in the general population,
which is not known in most nations, especially for females
and subjects younger than 65 years. A further determinant
of the cost-effectiveness is the availability of tools for se-
lection of subgroups at higher risk, which lies in the
knowledge of risk factors associated with the disease. The
RoCAV study will then answer to two main questions, re-
garding prevalence in Northern Italy among all age and
sex classes at risk as well as regarding risk factors or risk
score which could be used to select subjects to be in-
cluded in a screening program.
The prevalence threshold for cost-effectiveness of a
screening program is considered to be 0.5–1.6% preva-
lence in 65-year old males from Western Countries [39].
Several studies collected AAA prevalence data from the
general population, using a population-based study de-
sign or prevention intervention trials. Most data avail-
able are from population of 65-years old males, showing
a prevalence of 1.1–1.7% [1]. Prevalence in younger
people is lower, however few data are available. For this
subgroup, a lower cost-effectiveness threshold should be
considered, due to higher QALY gained with a screening
program. A recent meta-analysis showed that prevalence
in females is greater than 1% only after 70 years [40],
with a large heterogeneity across countries. It is note-
worthy that recently a decline in AAA prevalence was
observed, since the improved CVD risk management
and a decline in smoking. However, at the same time,
surgical techniques improved and longevity increased,
contributing to decrease the expected threshold for cost-
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effectiveness in different context [1]. AAA prevalence is
then highly heterogeneous across countries and the epi-
demiological context are changing. Collecting regional
data from the general population is strongly requested.
The main aim of the RoCAV was to verify the AAA
prevalence for the first time in a Northern Italian popu-
lation, using a population-based approach and standard-
ized methods for a screening program, for a rapid
translation in the real public health context.
Cost-effectiveness of a screening program could be im-
proved tailoring the intervention to a subgroup with a
higher prevalence, identified basing on risk factors preva-
lence. The risk factors associated with AAA risk are smok-
ing, family history of AAA and hypertension, along with age
and sex. In different context, elderly males having one of
more of this risk factors are suggested to undergo an ultra-
sound imaging scan of the abdominal aorta. Smoking is the
main risk factor, which explain about 3 out of 4 cases. Hav-
ing a previous CVD is suggested to be an important risk
marker [15, 16], due to shared risk factors between AAA
and CVD. The association with more CVD risk factors and
with CVD history suggests to use the same risk assessment
tool used for major CVD, like CVD risk scores. This was
the second aim of the RoCAV study, very recently addressed
also by Jones et al. in selected populations [41]. Our study
will address this question in the context of a large sample,
randomly selected from the general population.
However, part of the AAA phenotypic variability in
the population remains unexplained, due to the effect of
other known risk factors, exerting a small effect, or less
known conditions not yet well studied, with a strong ef-
fect. The large set of data collected in the RoCAV study,
their novelty (PWV, ABI, diet scores), the validated tools
used, the possibility to measure new biomarkers in sam-
ples stored in biobank (metabolomics and proteomics)
will address this question. Furthermore, it is expected
than a large impact would have epigenetic and genetic
mechanisms [17, 18], alone or in interaction with envir-
onmental variables, both measurable in biobank samples.
Therefore, the availability of this large set of data will
allow to model an AAA risk score algorithm for risk
assessment, potentially useful to select subgroups of
patients at higher risk to be included in a screening
program, as for risk stratification of major CVD.
Despite the importance of AAA, the main burden of
disease in public health is represented by CVD and can-
cer. The large set of CVD-related risk factors allow to
study also new markers for CVD, as well as for any other
disease present in the general population. Conditions
other than AAA, such as atrial fibrillation, could be in
fact potentially prevented with a screening program in
the general population or in subgroups at high risk [22].
The RoCAV study has several advantages. It is a paper-
less study, data collection (questionnaires as well as
ECG, spirometry, ABI-PWV and ultrasound parameters)
was totally computerized, reducing potential errors dur-
ing a delayed data input. Moreover, the use of barcodes
to identify patients limited the possibility of wrong as-
signment to the patient electronic record. Furthermore,
a large set of data were collected, using previously
validated methods and innovative tools. Finally, the
availability of sample stored in biobank for future ana-
lysis will allow the evaluation of OMICs and other
biomarkers.
The expected impact of the RoCAV project is: 1) esti-
mation of the AAA prevalence in the general population
of Northern Italy in males older than 50 years and in
females older than 60 years and the potential implementa-
tion of a screening program to the whole region; 2) evalu-
ation of the clinical utility of standard CVD and AAA risk
scores in AAA risk stratification, to improve selection of
subjects to be included in the AAA screening program; 3)
long-term estimation of cost-effectiveness of the screening
program in the local context, considering the possibility to
reduce also CVD-specific and all-cause mortality.
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